All About Multiple Sclerosis

More MS news articles for October 2003

An Immunomodulatory GpG Oligonucleotide for the Treatment of Autoimmunity via the Innate and Adaptive Immune Systems

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14568974&dopt=Abstract

J Immunol. 2003 Nov 1;171(9):4920-4926
Ho PP, Fontoura P, Ruiz PJ, Steinman L, Garren H.
Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Beckman Center for Molecular Medicine, Stanford, CA 94305. Department of Medicine, California Pacific Medical Center, San Francisco, CA 94115. University Department of Neurology, Hospital Egas Moniz, Lisbon, Portugal. Bayhill Therapeutics, Inc., Palo Alto, CA 94303.

Bacterial DNA and immunostimulatory CpG oligodeoxynucleotides (ODNs) activate the innate immune system to produce proinflammatory cytokines.

Shown to be potent Th1-like adjuvants, stimulatory CpG motifs are currently used as effective therapeutic vaccines for various animal models of infectious diseases, tumors, allergies, and autoimmune diseases.

In this study, we show that the application of an immunomodulatory GpG ODN, with a single base switch from CpG to GpG, can effectively inhibit the activation of Th1 T cells associated with autoimmune disease.

Moreover, this immunomodulatory GpG ODN suppresses the severity of experimental autoimmune encephalomyelitis in mice, a prototypic Th1-mediated animal disease model for multiple sclerosis.